Chimeric Antigen Receptor-Modified NK-92 Cells
AssigneeNantKwest, Inc.
InventorsLaurent H. Boissel, Hans G. Klingemann
Life of this patent
Estimating the term…
Abstract
Provided are NK-92 cells expressing a chimeric antigen receptor (CAR). The CAR can comprise an intracellular domain of FcεRIγ. Also described are methods for treating a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer or a viral infection, comprising administering to the patient NK-92-CAR cells.
Claims31
A genetically modified NK cell carrying a membrane bound recombinant chimeric antigen receptor (CAR) that is encoded on a transfected recombinant plasmid and that comprises in a single polypeptide chain:
- an extracellular binding domain, a hinge domain, a transmembrane domain, and a FcεRIγ signaling domain;
- and
- wherein the NK cell is an NK-92 cell.
(canceled)
A genetically modified NK cell, comprising:
- a recombinant nucleic acid encoding a chimeric antigen receptor (CAR), wherein the recombinant nucleic acid is a transfected plasmid;
- wherein the NK cell is an NK-92 cell;
- wherein the CAR comprises in a single polypeptide chain an extracellular binding domain, a hinge domain, a transmembrane domain, and a FcεRIγ signaling domain.
(canceled)
(canceled)
Dependencies are inferred from the claim text.